Bedel Financial Consulting’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $301M | Sell |
327,576
-461
| -0.1% | -$467K | 33.92% | 1 |
|
|
2025
Q4 | $353M | Sell |
328,037
-444
| -0.1% | -$425K | 37.93% | 1 |
|
|
2025
Q3 | $251M | Sell |
328,481
-209
| -0.1% | -$156K | 32% | 1 |
|
|
2025
Q2 | $256M | Buy |
328,690
+26
| +0% | +$20.2K | 34.95% | 1 |
|
|
2025
Q1 | $255M | Buy |
328,664
+2,800
| +0.9% | +$2.33M | 36.5% | 1 |
|
|
2024
Q4 | $274M | Buy |
325,864
+9
| +0% | +$7.45K | 38.11% | 1 |
|
|
2024
Q3 | $289M | Sell |
325,855
-1,255
| -0.4% | -$1.13M | 40.73% | 1 |
|
|
2024
Q2 | $296M | Sell |
327,110
-3,089
| -0.9% | -$2.47M | 43.4% | 1 |
|
|
2024
Q1 | $257M | Sell |
330,199
-314
| -0.1% | -$223K | 40.29% | 1 |
|
|
2023
Q4 | $193M | Buy |
330,513
+4,972
| +2% | +$2.9M | 35.31% | 1 |
|
|
2023
Q3 | $175M | Buy |
325,541
+3,376
| +1% | +$1.74M | 35.4% | 1 |
|
|
2023
Q2 | $151M | Sell |
322,165
-279
| -0.1% | -$117K | 31.56% | 1 |
|
|
2023
Q1 | $111M | Sell |
322,444
-568
| -0.2% | -$192K | 26.97% | 1 |
|
|
2022
Q4 | $118M | Sell |
323,012
-394
| -0.1% | -$140K | 29.38% | 1 |
|
|
2022
Q3 | $118M | Sell |
323,406
-8,933
| -3% | -$2.83M | 31.3% | 1 |
|
|
2022
Q2 | $108M | Buy |
332,339
+242
| +0.1% | +$72.6K | 31.52% | 1 |
|
|
2022
Q1 | $95.1M | Buy |
332,097
+590
| +0.2% | +$152K | 29.88% | 1 |
|
|
2021
Q4 | $91.6M | Sell |
331,507
-1,760
| -0.5% | -$446K | 28.48% | 1 |
|
|
2021
Q3 | $77M | Buy |
333,267
+2,603
| +0.8% | +$642K | 26.43% | 1 |
|
|
2021
Q2 | $75.9M | Buy |
330,664
+792
| +0.2% | +$159K | 26.42% | 1 |
|
|
2021
Q1 | $61.6M | Sell |
329,872
-1,017
| -0.3% | -$199K | 23.84% | 1 |
|
|
2020
Q4 | $55.9M | Sell |
330,889
-3,650
| -1% | -$545K | 24.79% | 1 |
|
|
2020
Q3 | $49.5M | Sell |
334,539
-191
| -0.1% | -$29.6K | 24.76% | 1 |
|
|
2020
Q2 | $55M | Sell |
334,730
-1,675
| -0.5% | -$257K | 29.63% | 1 |
|
|
2020
Q1 | $46.7M | Sell |
336,405
-18,465
| -5% | -$2.54M | 30.86% | 1 |
|
|
2019
Q4 | $46.6M | Sell |
354,870
-2,468
| -0.7% | -$286K | 26.45% | 1 |
|
|
2019
Q3 | $40M | Buy |
357,338
+111
| +0% | +$12.4K | 24.05% | 1 |
|
|
2019
Q2 | $39.6M | Buy |
357,227
+822
| +0.2% | +$96.8K | 24.05% | 1 |
|
|
2019
Q1 | $46.2M | Sell |
356,405
-3,183
| -0.9% | -$387K | 29.5% | 1 |
|
|
2018
Q4 | $41.6M | Sell |
359,588
-1,624
| -0.4% | -$181K | 29.94% | 1 |
|
|
2018
Q3 | $40.1M | Sell |
361,212
-4,850
| -1% | -$485K | 26.76% | 1 |
|
|
2018
Q2 | $31.2M | Buy |
366,062
+2,178
| +0.6% | +$179K | 22.97% | 1 |
|
|
2018
Q1 | $28.2M | Buy |
363,884
+16,239
| +5% | +$1.31M | 21.4% | 1 |
|
|
2017
Q4 | $29.4M | Buy |
+347,645
| New | +$29.6M | 26.42% | 1 |
|
Other funds holding LLY
VCM
VPM
Bedel Financial Consulting's LLY Position: Q1 2026 in Review
Bedel Financial Consulting reduced its Eli Lilly (LLY) stake by 0.14% in Q1 2026, selling an estimated $467K and leaving 327,576 shares worth $301M. The position accounts for 33.92% of the portfolio, ranked #1.
Bedel Financial Consulting first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. The position peaked at $353M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Bedel Financial Consulting held 327,576 shares of Eli Lilly worth $301M as of Q1 2026.
- Bedel Financial Consulting sold 461 Eli Lilly shares in Q1 2026, an estimated $467K.
- Eli Lilly made up 33.92% of Bedel Financial Consulting's portfolio in Q1 2026, its #1 holding.
- Bedel Financial Consulting first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- Bedel Financial Consulting's Eli Lilly position peaked at $353M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Bedel Financial Consulting's 13F filing for Q1 2026, filed 4 May 2026.